Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability

  • Meriggioli M
  • Ciafaloni E
  • Al-Hayk K
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • M.N. Meriggioli

  • E. Ciafaloni

  • K.A. Al-Hayk

  • J. Rowin

  • B. Tucker-Lipscomb

  • J.M. Massey

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free